Acebutolol
Acebutolol may decrease the bronchodilatory activities of Indacaterol.
Alclometasone
Indacaterol may increase the hypokalemic activities of Alclometasone.
Aldosterone
Indacaterol may increase the hypokalemic activities of Aldosterone.
Advertisement
Alprenolol
Alprenolol may decrease the bronchodilatory activities of Indacaterol.
AMBROXOL ACEFYLLINATE
The risk or severity of adverse effects can be increased when Ambroxol acefyllinate is combined with Indacaterol.
Ambroxol-Theophylline-7-Acetate
The risk or severity of adverse effects can be increased when Ambroxol acefyllinate is combined with Indacaterol.
Advertisement
Amcinonide
Indacaterol may increase the hypokalemic activities of Amcinonide.
Amineptin
The risk or severity of adverse effects can be increased when Amineptine is combined with Indacaterol.
Aminophylline
The risk or severity of adverse effects can be increased when Aminophylline is combined with Indacaterol.
Advertisement
Amiodarone
The metabolism of Indacaterol can be decreased when combined with Amiodarone.
Amitriptyline
The risk or severity of adverse effects can be increased when Amitriptyline is combined with Indacaterol.
Amoxapine
The therapeutic efficacy of Indacaterol can be decreased when used in combination with Amoxapine.
Amphetamine
The risk or severity of adverse effects can be increased when Amphetamine is combined with Indacaterol.
Anagrelide
Indacaterol may increase the QTc-prolonging activities of Anagrelide.
Androstenedione
Indacaterol may increase the hypokalemic activities of Androstenedione.
Apalutamide
The serum concentration of Indacaterol can be decreased when it is combined with Apalutamide.
Aprepitant
The serum concentration of Indacaterol can be increased when it is combined with Aprepitant.
Arsenic Trioxide
Indacaterol may increase the QTc-prolonging activities of Arsenic trioxide.
Artemether
Indacaterol may increase the QTc-prolonging activities of Artemether.
Asenapine
Indacaterol may increase the QTc-prolonging activities of Asenapine.
Atazanavir
The metabolism of Indacaterol can be decreased when combined with Atazanavir.
Atenolol
Atenolol may decrease the bronchodilatory activities of Indacaterol.
Atomoxetine
Atomoxetine may increase the tachycardic activities of Indacaterol.
Atosiban
The risk or severity of adverse effects can be increased when Indacaterol is combined with Atosiban.
Azithromycin
Indacaterol may increase the QTc-prolonging activities of Azithromycin.
Azosemide
Indacaterol may increase the hypokalemic activities of Azosemide.
Beclomethasone Dipropionate
Indacaterol may increase the hypokalemic activities of Beclomethasone dipropionate.
Bedaquiline
Indacaterol may increase the QTc-prolonging activities of Bedaquiline.
Bendroflumethiazide
Indacaterol may increase the hypokalemic activities of Bendroflumethiazide.
BETAHISTINE
The therapeutic efficacy of Indacaterol can be decreased when used in combination with Betahistine.
Betamethasone
Indacaterol may increase the hypokalemic activities of Betamethasone.
Betaxolol
Betaxolol may decrease the bronchodilatory activities of Indacaterol.
Bisoprolol
Bisoprolol may decrease the bronchodilatory activities of Indacaterol.
Boceprevir
The metabolism of Indacaterol can be decreased when combined with Boceprevir.
Bopindolol
Bopindolol may decrease the bronchodilatory activities of Indacaterol.
Bortezomib
The metabolism of Indacaterol can be decreased when combined with Bortezomib.
Bosentan
The serum concentration of Indacaterol can be decreased when it is combined with Bosentan.
Budesonide
Indacaterol may increase the hypokalemic activities of Budesonide.
Bumetanide
Indacaterol may increase the hypokalemic activities of Bumetanide.
Bupranolol
Bupranolol may decrease the bronchodilatory activities of Indacaterol.
Caffeine
The risk or severity of adverse effects can be increased when Caffeine is combined with Indacaterol.
Carbamazepine
The metabolism of Indacaterol can be increased when combined with Carbamazepine.
Carteolol
Carteolol may decrease the bronchodilatory activities of Indacaterol.
Celiprolol
Celiprolol may decrease the bronchodilatory activities of Indacaterol.
Ceritinib
The serum concentration of Indacaterol can be increased when it is combined with Ceritinib.
Chloroquine
Indacaterol may increase the QTc-prolonging activities of Chloroquine.
Chlorothiazide
Indacaterol may increase the hypokalemic activities of Chlorothiazide.
Chlorpromazine
Indacaterol may increase the QTc-prolonging activities of Chlorpromazine.
Chlorthalidone
Indacaterol may increase the hypokalemic activities of Chlorthalidone.
Ciclesonide
Indacaterol may increase the hypokalemic activities of Ciclesonide.
Ciprofloxacin
Indacaterol may increase the QTc-prolonging activities of Ciprofloxacin.
Cisapride
Indacaterol may increase the QTc-prolonging activities of Cisapride.
Citalopram
Indacaterol may increase the QTc-prolonging activities of Citalopram.
Clarithromycin
The metabolism of Indacaterol can be decreased when combined with Clarithromycin.
Clemastine
The metabolism of Indacaterol can be decreased when combined with Clemastine.
Clobetasol
Indacaterol may increase the hypokalemic activities of Clobetasol.
Clobetasol Propionate
Indacaterol may increase the hypokalemic activities of Clobetasol propionate.
Clobetasone
Indacaterol may increase the hypokalemic activities of Clobetasone.
Clocortolone
Indacaterol may increase the hypokalemic activities of Clocortolone.
Clomipramine
The risk or severity of adverse effects can be increased when Clomipramine is combined with Indacaterol.
Clotrimazole
The metabolism of Indacaterol can be decreased when combined with Clotrimazole.
Clozapine
Indacaterol may increase the QTc-prolonging activities of Clozapine.
Cobicistat
The metabolism of Indacaterol can be decreased when combined with Cobicistat.
Conivaptan
The serum concentration of Conivaptan can be increased when it is combined with Indacaterol.
Cortisone Acetate
Indacaterol may increase the hypokalemic activities of Cortisone acetate.
Crizotinib
The metabolism of Indacaterol can be decreased when combined with Crizotinib.
Cyclobenzaprine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Indacaterol.
Cyclopenthiazide
Indacaterol may increase the hypokalemic activities of Cyclopenthiazide.
Cyclosporine
The metabolism of Indacaterol can be decreased when combined with Cyclosporine.
Dabrafenib
The serum concentration of Indacaterol can be decreased when it is combined with Dabrafenib.
Darunavir
The metabolism of Indacaterol can be decreased when combined with Darunavir.
Dasatinib
The serum concentration of Indacaterol can be increased when it is combined with Dasatinib.
Dasatinib Anhydrous
The serum concentration of Indacaterol can be increased when it is combined with Dasatinib.
Deferasirox
The serum concentration of Indacaterol can be decreased when it is combined with Deferasirox.
Deflazacort
Indacaterol may increase the hypokalemic activities of Deflazacort.
Delavirdine
The metabolism of Indacaterol can be decreased when combined with Delavirdine.
Desipramine
The risk or severity of adverse effects can be increased when Desipramine is combined with Indacaterol.
Desonide
Indacaterol may increase the hypokalemic activities of Desonide.
Desoximetasone
Indacaterol may increase the hypokalemic activities of Desoximetasone.
Desoxycorticosterone acetate
Indacaterol may increase the hypokalemic activities of Desoxycorticosterone acetate.
Desoxycorticosterone Pivalate
Indacaterol may increase the hypokalemic activities of Desoxycorticosterone Pivalate.
Dexamethasone
Indacaterol may increase the hypokalemic activities of Dexamethasone.
Diflorasone
Indacaterol may increase the hypokalemic activities of Diflorasone.
Diflucortolone
Indacaterol may increase the hypokalemic activities of Difluocortolone.
Difluprednate
Indacaterol may increase the hypokalemic activities of Difluprednate.
Dihydroergotamine
The metabolism of Indacaterol can be decreased when combined with Dihydroergotamine.
Diltiazem
The metabolism of Indacaterol can be decreased when combined with Diltiazem.
Disopyramide
Indacaterol may increase the QTc-prolonging activities of Disopyramide.
Dofetilide
Indacaterol may increase the QTc-prolonging activities of Dofetilide.
Dolasetron
Indacaterol may increase the QTc-prolonging activities of Dolasetron.
Domperidone
Indacaterol may increase the QTc-prolonging activities of Domperidone.
Dothiepin
The risk or severity of adverse effects can be increased when Dosulepin is combined with Indacaterol.
Doxepin
The risk or severity of adverse effects can be increased when Doxepin is combined with Indacaterol.
Doxycycline
The metabolism of Indacaterol can be decreased when combined with Doxycycline.
Doxycycline Anhydrous
The metabolism of Indacaterol can be decreased when combined with Doxycycline.
Dronedarone
Indacaterol may increase the QTc-prolonging activities of Dronedarone.
Droperidol
Indacaterol may increase the QTc-prolonging activities of Droperidol.
Dyphylline
The risk or severity of adverse effects can be increased when Dyphylline is combined with Indacaterol.
Eliglustat
Indacaterol may increase the QTc-prolonging activities of Eliglustat.
Enzalutamide
The serum concentration of Indacaterol can be decreased when it is combined with Enzalutamide.
Erythromycin
The metabolism of Indacaterol can be decreased when combined with Erythromycin.
Escitalopram
Indacaterol may increase the QTc-prolonging activities of Escitalopram.
Esmolol
Esmolol may decrease the bronchodilatory activities of Indacaterol.
Estrone
Indacaterol may increase the hypokalemic activities of Estrone.
Ethacrynate
Indacaterol may increase the hypokalemic activities of Etacrynic acid.
Ethacrynic Acid
Indacaterol may increase the hypokalemic activities of Etacrynic acid.
Flecainide
Indacaterol may increase the QTc-prolonging activities of Flecainide.
Fluconazole
The metabolism of Indacaterol can be decreased when combined with Fluconazole.
Fludrocortisone
Indacaterol may increase the hypokalemic activities of Fludrocortisone.
Flumethasone
Indacaterol may increase the hypokalemic activities of Flumethasone.
Flunisolide
Indacaterol may increase the hypokalemic activities of Flunisolide.
Flunisolide Anhydrous (obsolete)
Indacaterol may increase the hypokalemic activities of Flunisolide.
Fluocinolone Acetonide
Indacaterol may increase the hypokalemic activities of Fluocinolone Acetonide.
Fluocinonide
Indacaterol may increase the hypokalemic activities of Fluocinonide.
Fluocortolone
Indacaterol may increase the hypokalemic activities of Fluocortolone.
Fluorometholone
Indacaterol may increase the hypokalemic activities of Fluorometholone.
Fluoxetine
Indacaterol may increase the QTc-prolonging activities of Fluoxetine.
Flupenthixol
Indacaterol may increase the QTc-prolonging activities of Flupentixol.
FLUPREDNIDENE
Indacaterol may increase the hypokalemic activities of Fluprednidene.
Fluprednisolone
Indacaterol may increase the hypokalemic activities of Fluprednisolone.
Flurandrenolide
Indacaterol may increase the hypokalemic activities of Flurandrenolide.
Fluticasone Furoate
Indacaterol may increase the hypokalemic activities of Fluticasone furoate.
Fluticasone propionate
Indacaterol may increase the hypokalemic activities of Fluticasone propionate.
Fluvoxamine
The metabolism of Indacaterol can be decreased when combined with Fluvoxamine.
Formestane
Indacaterol may increase the hypokalemic activities of Formestane.
Fosamprenavir
The metabolism of Indacaterol can be decreased when combined with Fosamprenavir.
Fosaprepitant
The serum concentration of Indacaterol can be increased when it is combined with Fosaprepitant.
Fosphenytoin
The metabolism of Indacaterol can be increased when combined with Fosphenytoin.
Furazolidone
The risk or severity of adverse effects can be increased when Furazolidone is combined with Indacaterol.
Furosemide
Indacaterol may increase the hypokalemic activities of Furosemide.
Fusidate
The serum concentration of Indacaterol can be increased when it is combined with Fusidic Acid.
Fusidic Acid
The serum concentration of Indacaterol can be increased when it is combined with Fusidic Acid.
Gadobenate
Indacaterol may increase the QTc-prolonging activities of Gadobenic acid.
Gemifloxacin
Indacaterol may increase the QTc-prolonging activities of Gemifloxacin.
Gemifloxacin Mesylate
Indacaterol may increase the QTc-prolonging activities of Gemifloxacin.
Goserelin
Indacaterol may increase the QTc-prolonging activities of Goserelin.
Granisetron
Indacaterol may increase the QTc-prolonging activities of Granisetron.
Halcinonide
Indacaterol may increase the hypokalemic activities of Halcinonide.
Halobetasol
Indacaterol may increase the hypokalemic activities of Ulobetasol.
Haloperidol
Indacaterol may increase the QTc-prolonging activities of Haloperidol.
Hydrochlorothiazide
Indacaterol may increase the hypokalemic activities of Hydrochlorothiazide.
Hydrocortisone
Indacaterol may increase the hypokalemic activities of Hydrocortisone.
Hydroflumethiazide
Indacaterol may increase the hypokalemic activities of Hydroflumethiazide.
Hypoxis hemerocallidea root extract
The serum concentration of Indacaterol can be decreased when it is combined with St. John's Wort.
Ibutilide
Indacaterol may increase the QTc-prolonging activities of Ibutilide.
Idelalisib
The metabolism of Indacaterol can be decreased when combined with Idelalisib.
Iloperidone
Indacaterol may increase the QTc-prolonging activities of Iloperidone.
Imatinib
The metabolism of Indacaterol can be decreased when combined with Imatinib.
Imipramine
The risk or severity of adverse effects can be increased when Imipramine is combined with Indacaterol.
Indapamide
Indacaterol may increase the hypokalemic activities of Indapamide.
Indinavir
The metabolism of Indacaterol can be decreased when combined with Indinavir.
INDINAVIR ANHYDROUS
The metabolism of Indacaterol can be decreased when combined with Indinavir.
Iproniazid
The risk or severity of adverse effects can be increased when Iproniazid is combined with Indacaterol.
Isavuconazole
The serum concentration of Indacaterol can be increased when it is combined with Isavuconazole.
Isavuconazonium
The metabolism of Indacaterol can be decreased when combined with Isavuconazonium.
Isocarboxazid
The risk or severity of adverse effects can be increased when Isocarboxazid is combined with Indacaterol.
Isradipine
The metabolism of Indacaterol can be decreased when combined with Isradipine.
Itraconazole
The metabolism of Indacaterol can be decreased when combined with Itraconazole.
Ivacaftor
The serum concentration of Indacaterol can be increased when it is combined with Ivacaftor.
Ketoconazole
The metabolism of Indacaterol can be decreased when combined with Ketoconazole.
Lenvatinib
Indacaterol may increase the QTc-prolonging activities of Lenvatinib.
Lenvatinib Mesylate
Indacaterol may increase the QTc-prolonging activities of Lenvatinib.
Leuprolide
Indacaterol may increase the QTc-prolonging activities of Leuprolide.
Levofloxacin
Indacaterol may increase the QTc-prolonging activities of Levofloxacin.
Levofloxacin Anhydrous
Indacaterol may increase the QTc-prolonging activities of Levofloxacin.
Lopinavir
The metabolism of Indacaterol can be decreased when combined with Lopinavir.
Loteprednol
Indacaterol may increase the hypokalemic activities of Loteprednol.
Lovastatin
The metabolism of Indacaterol can be decreased when combined with Lovastatin.
Luliconazole
The serum concentration of Indacaterol can be increased when it is combined with Luliconazole.
Lumacaftor
The serum concentration of Indacaterol can be decreased when it is combined with Lumacaftor.
Lumefantrine
Indacaterol may increase the QTc-prolonging activities of Lumefantrine.
Medrysone
Indacaterol may increase the hypokalemic activities of Medrysone.
Methadone
Indacaterol may increase the QTc-prolonging activities of Methadone.
Methyclothiazide
Indacaterol may increase the hypokalemic activities of Methyclothiazide.
Methylene blue
The risk or severity of adverse effects can be increased when Methylene blue is combined with Indacaterol.
Methylprednisolone
Indacaterol may increase the hypokalemic activities of Methylprednisolone.
Metolazone
Indacaterol may increase the hypokalemic activities of Metolazone.
Metoprolol
Metoprolol may decrease the bronchodilatory activities of Indacaterol.
Mifepristone
The serum concentration of Indacaterol can be increased when it is combined with Mifepristone.
Minaprine
The risk or severity of adverse effects can be increased when Minaprine is combined with Indacaterol.
Mirtazapine
The risk or severity of adverse effects can be increased when Mirtazapine is combined with Indacaterol.
Mitotane
The serum concentration of Indacaterol can be decreased when it is combined with Mitotane.
Moclobemide
The risk or severity of adverse effects can be increased when Moclobemide is combined with Indacaterol.
Mometasone
Indacaterol may increase the hypokalemic activities of Mometasone.
Moxifloxacin
Indacaterol may increase the QTc-prolonging activities of Moxifloxacin.
Nebivolol
Nebivolol may decrease the bronchodilatory activities of Indacaterol.
Nefazodone
The metabolism of Indacaterol can be decreased when combined with Nefazodone.
Nelfinavir
The metabolism of Indacaterol can be decreased when combined with Nelfinavir.
Netupitant
The serum concentration of Indacaterol can be increased when it is combined with Netupitant.
Nevirapine
The metabolism of Indacaterol can be increased when combined with Nevirapine.
Nialamide
The risk or severity of adverse effects can be increased when Nialamide is combined with Indacaterol.
Nilotinib
Indacaterol may increase the QTc-prolonging activities of Nilotinib.
Nortriptyline
The risk or severity of adverse effects can be increased when Nortriptyline is combined with Indacaterol.
Ofloxacin
Indacaterol may increase the QTc-prolonging activities of Ofloxacin.
Olaparib
The metabolism of Indacaterol can be decreased when combined with Olaparib.
Ondansetron
Indacaterol may increase the QTc-prolonging activities of Ondansetron.
Opipramol
The risk or severity of adverse effects can be increased when Opipramol is combined with Indacaterol.
Osimertinib
The serum concentration of Indacaterol can be increased when it is combined with Osimertinib.
Oxprenolol
Oxprenolol may decrease the bronchodilatory activities of Indacaterol.
Palbociclib
The serum concentration of Indacaterol can be increased when it is combined with Palbociclib.
Paliperidone
Indacaterol may increase the QTc-prolonging activities of Paliperidone.
Panobinostat
Indacaterol may increase the QTc-prolonging activities of Panobinostat.
Paramethasone
Indacaterol may increase the hypokalemic activities of Paramethasone.
Pargyline
The risk or severity of adverse effects can be increased when Pargyline is combined with Indacaterol.
Pazopanib
Indacaterol may increase the QTc-prolonging activities of Pazopanib.
Pentamidine
Indacaterol may increase the QTc-prolonging activities of Pentamidine.
Pentobarbital
The metabolism of Indacaterol can be increased when combined with Pentobarbital.
Perflutren
Indacaterol may increase the QTc-prolonging activities of Perflutren.
Phenelzine
The risk or severity of adverse effects can be increased when Phenelzine is combined with Indacaterol.
Phenobarbital
The metabolism of Indacaterol can be increased when combined with Phenobarbital.
Phenytoin
The metabolism of Indacaterol can be increased when combined with Phenytoin.
Pimozide
Indacaterol may increase the QTc-prolonging activities of Pimozide.
Piretanide
Indacaterol may increase the hypokalemic activities of Piretanide.
Polythiazide
Indacaterol may increase the hypokalemic activities of Polythiazide.
Posaconazole
The metabolism of Indacaterol can be decreased when combined with Posaconazole.
Prasterone
Indacaterol may increase the hypokalemic activities of Prasterone.
Prednicarbate
Indacaterol may increase the hypokalemic activities of Prednicarbate.
Prednisolone
Indacaterol may increase the hypokalemic activities of Prednisolone.
Prednisone
Indacaterol may increase the hypokalemic activities of Prednisone.
Pregnenolone
Indacaterol may increase the hypokalemic activities of Pregnenolone.
Primaquine
Indacaterol may increase the QTc-prolonging activities of Primaquine.
Primidone
The metabolism of Indacaterol can be increased when combined with Primidone.
Procainamide
Indacaterol may increase the QTc-prolonging activities of Procainamide.
Procarbazine
The risk or severity of adverse effects can be increased when Procarbazine is combined with Indacaterol.
Promazine
Indacaterol may increase the QTc-prolonging activities of Promazine.
Propafenone
Indacaterol may increase the QTc-prolonging activities of Propafenone.
Protriptyline
The risk or severity of adverse effects can be increased when Protriptyline is combined with Indacaterol.
Quetiapine
Indacaterol may increase the QTc-prolonging activities of Quetiapine.
Quetiapine fumarate
Indacaterol may increase the QTc-prolonging activities of Quetiapine.
Quinethazone
Indacaterol may increase the hypokalemic activities of Quinethazone.
Quinidine
Indacaterol may increase the QTc-prolonging activities of Quinidine.
Quinine
Indacaterol may increase the QTc-prolonging activities of Quinine.
Ranolazine
The serum concentration of Indacaterol can be increased when it is combined with Ranolazine.
Rasagiline
The risk or severity of adverse effects can be increased when Rasagiline is combined with Indacaterol.
Rifabutin
The metabolism of Indacaterol can be increased when combined with Rifabutin.
Rifampin
The metabolism of Indacaterol can be increased when combined with Rifampicin.
Rifapentine
The metabolism of Indacaterol can be increased when combined with Rifapentine.
Rimexolone
Indacaterol may increase the hypokalemic activities of Rimexolone.
Rucaparib
The metabolism of Indacaterol can be decreased when combined with Rucaparib.
Saquinavir
The metabolism of Indacaterol can be decreased when combined with Saquinavir.
Saquinavir Mesylate
The metabolism of Indacaterol can be decreased when combined with Saquinavir.
Sarilumab
The therapeutic efficacy of Indacaterol can be decreased when used in combination with Sarilumab.
Selegiline
The risk or severity of adverse effects can be increased when Selegiline is combined with Indacaterol.
Sildenafil
The metabolism of Indacaterol can be decreased when combined with Sildenafil.
Siltuximab
The serum concentration of Indacaterol can be decreased when it is combined with Siltuximab.
Simeprevir
The serum concentration of Indacaterol can be increased when it is combined with Simeprevir.
Sotalol
Indacaterol may increase the QTc-prolonging activities of Sotalol.
ST. JOHN'S WORT EXTRACT
The serum concentration of Indacaterol can be decreased when it is combined with St. John's Wort.
Sulfisoxazole
The metabolism of Indacaterol can be decreased when combined with Sulfisoxazole.
Telaprevir
The metabolism of Indacaterol can be decreased when combined with Telaprevir.
Telavancin
Indacaterol may increase the QTc-prolonging activities of Telavancin.
Telithromycin
The metabolism of Indacaterol can be decreased when combined with Telithromycin.
Tetrabenazine
Indacaterol may increase the QTc-prolonging activities of Tetrabenazine.
Theophylline
The risk or severity of adverse effects can be increased when Theophylline is combined with Indacaterol.
Theophylline anhydrous
The risk or severity of adverse effects can be increased when Theophylline is combined with Indacaterol.
Thioridazine
Indacaterol may increase the QTc-prolonging activities of Thioridazine.
Tianeptine
The risk or severity of adverse effects can be increased when Tianeptine is combined with Indacaterol.
Ticlopidine
The metabolism of Indacaterol can be decreased when combined with Ticlopidine.
Timolol
Timolol may decrease the bronchodilatory activities of Indacaterol.
Timolol Anhydrous
Timolol may decrease the bronchodilatory activities of Indacaterol.
Tixocortol
Indacaterol may increase the hypokalemic activities of Tixocortol.
Tocilizumab
The serum concentration of Indacaterol can be decreased when it is combined with Tocilizumab.
Toloxatone
The risk or severity of adverse effects can be increased when Toloxatone is combined with Indacaterol.
Toremifene
Indacaterol may increase the QTc-prolonging activities of Toremifene.
Torsemide
Indacaterol may increase the hypokalemic activities of Torasemide.
Tranylcypromine
The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Indacaterol.
Triamcinolone
Indacaterol may increase the hypokalemic activities of Triamcinolone.
Trichlormethiazide
Indacaterol may increase the hypokalemic activities of Trichlormethiazide.
Trimipramine
The risk or severity of adverse effects can be increased when Trimipramine is combined with Indacaterol.
Vandetanib
Indacaterol may increase the QTc-prolonging activities of Vandetanib.
Vemurafenib
The serum concentration of Indacaterol can be increased when it is combined with Vemurafenib.
Venlafaxine
The metabolism of Indacaterol can be decreased when combined with Venlafaxine.
Verapamil
The metabolism of Indacaterol can be decreased when combined with Verapamil.
Voriconazole
The metabolism of Indacaterol can be decreased when combined with Voriconazole.
Ziprasidone
Indacaterol may increase the QTc-prolonging activities of Ziprasidone.
Zuclopenthixol
Indacaterol may increase the QTc-prolonging activities of Zuclopenthixol.
